<DOC>
	<DOCNO>NCT01396135</DOCNO>
	<brief_summary>This Phase 1 study first clinical trial conduct Japanese subject . The pharmacokinetics , safety tolerability single multiple dos CP-601,927 evaluate Japanese , healthy , non-smoking subject .</brief_summary>
	<brief_title>A Phase 1 Study To Investigate The Pharmacokinetics , Safety And Tolerability Of CP-601,927 In Healthy Japanese Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female Japanese subject age 18 55 year , inclusive . Japanese define able document 4 grandparent Japanese born Japan . Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Females childbearing potential . Subjects regular ( daily weekly ) use tobacco product nicotine currently within past 6 month . Subjects urine cotinine concentration &gt; 100 ng/mL time study exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Healthy</keyword>
	<keyword>Japanese</keyword>
	<keyword>Non-smokers</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>CP-601</keyword>
	<keyword>927</keyword>
</DOC>